Novo Holdings A/S’s LAVA Therapeutics LVTX Stock Holding History

Novo Holdings A/S’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,878,194	Closed	-$2.97M	–	37
2023 Q4	$2.97M	Sell	1,878,194 -521,806	-22%	-$745K	0.18%	35
2023 Q3	$3.53M	Hold	2,400,000	–	–	0.26%	35
2023 Q2	$4.87M	Sell	2,400,000 -670,558	-22%	-$1.24M	0.38%	38
2023 Q1	$5.1M	Sell	3,070,558 -256,754	-8%	-$719K	0.34%	43
2022 Q4	$11.6M	Hold	3,327,312	–	–	0.73%	36
2022 Q3	$15.2M	Hold	3,327,312	–	–	0.73%	28
2022 Q2	$9.82M	Hold	3,327,312	–	–	0.48%	38
2022 Q1	$14.6M	Hold	3,327,312	–	–	0.77%	24
2021 Q4	$18.3M	Hold	3,327,312	–	–	0.87%	23
2021 Q3	$19.7M	Hold	3,327,312	–	–	1.02%	23
2021 Q2	$36.2M	Hold	3,327,312	–	–	1.61%	18
2021 Q1	$50.5M	Buy	+3,327,312	New	+$45.7M	2.09%	14

Other funds holding LVTX

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Novo Holdings A/S's LVTX Position: Q1 2024 in Review

Novo Holdings A/S sold out of LAVA Therapeutics (LVTX) in Q1 2024, closing a stake of 1,878,194 shares — an estimated $2.97M sold.

Novo Holdings A/S first reported a position in LVTX in Q1 2021 and held it in 12 quarters. The position peaked at $50.5M in Q1 2021. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2024.

Novo Holdings A/S reported no remaining LAVA Therapeutics position as of Q1 2024 after selling out during the quarter.
Novo Holdings A/S sold 1,878,194 LAVA Therapeutics shares in Q1 2024, an estimated $2.97M.
Novo Holdings A/S first reported a position in LAVA Therapeutics in Q1 2021 and held it in 12 quarters.
Novo Holdings A/S's LAVA Therapeutics position peaked at $50.5M in Q1 2021.
20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2024.

Based on Novo Holdings A/S's 13F filing for Q1 2024, filed 15 May 2024.